Patricia Garbayo-Salmons, Eva Vilarrasa, Julio Bassas-Vila, Veronica Mora-Fernández, Irene Fuertes, Mar Luque-Luna, Rosa Fornons-Servent, Gemma Martin-Ezquerra, Rafael Sergio Aguayo-Ortiz, Joan Ceravalls, Jordi Mollet, Álvaro Gómez Tomás, Emili Masferrer, Oriol Corral-Magaña, Clara Matas-Nadal, Jorge Del Estal, Diana Fuertes Bailón, Joan Calvet, Jorge Romaní
BACKGROUND AND OBJECTIVES: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic. METHODS: We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022...
April 30, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV